Newsroom | 70603 results

MUMBAI, India & ORLANDO, Fla.--(BUSINESS WIRE)--LTM today announced the launch of the LTM Business Orchestration platform to orchestrate intelligent and autonomous enterprise operations across SAP....

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its first quarter 2026 financial results and provided a business update. “FB102 received Fast Track Designation from the FDA in celiac disease, highlighting the unmet need and reinforcing FB102’s potential to address the high unmet need in celiac disease. The clinical development for FB102 continue...

MCLEAN, Va.--(BUSINESS WIRE)--Melissa Kowalski, a science teacher at Put-in-Bay School in Ohio, was named the 2026 Shell Science Teaching Award recipient by the NSTA....

TEANECK, N.J.--(BUSINESS WIRE)--GC Biopharma Presents New Data at CIS 2026 to Expand Analytical Understanding of IVIG Product Characteristics...

CHICAGO--(BUSINESS WIRE)--As the global magnetic resonance (MR) community convenes for the International Society for Magnetic Resonance in Medicine (ISMRM) 2026 Annual Meeting, GE HealthCare (Nasdaq: GEHC) today announced advancements in research tools and MR systems that aim to accelerate discovery, strengthen collaboration across research programs, and turn innovation into meaningful clinical achievements. GE HealthCare continues to invest in advanced MR technology with its next-generation SI...

LOS ANGELES--(BUSINESS WIRE)--Researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States, will present 49 abstracts at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, including new findings on immunotherapy, precision medicine and emerging treatment strategies across blood cancers and solid tumors. These experts will partner with the global oncology community congregating in Chicago May 29-June 2 wi...

SOUTH SAN FRANCISCO, Calif. & TORONTO--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and ProTgen, a biotechnology company pioneering targeted Notch activators to reactivate the thymus and reconstitute the adaptive immune system, today announced a partnership to automate manufacturing and quality control of ProT-096, ProTgen's personalized progenitor T cell therapy for patients with refractory leukemia and other hematologic malignancies who ha...

NEW YORK--(BUSINESS WIRE)--IFF (NYSE: IFF)—a global leader in flavors, fragrances, food ingredients, health & bioscience—today announced the opening of its Vanilla Innovation Center in Madagascar, reinforcing vanilla as a strategic and priority tonality for IFF and strengthening its ability to innovate at origin. “The opening of the center marks an important step in how we approach vanilla innovation,” said Adam Jańczuk, Ph.D., senior vice president, research, creation and design, Taste, IF...

明尼阿波利斯--(BUSINESS WIRE)--(美国商业资讯)-- Edison®组织摧毁术系统及新型组织摧毁术治疗平台的研发企业HistoSonics今日宣布，已向美国食品药品管理局(FDA)提交De Novo申请，寻求扩大Edison®组织摧毁术系统的适用范围，纳入肾脏肿瘤破坏治疗。 这一里程碑标志着公司使命迈出重要一步：依托完全无创的技术变革实体肿瘤治疗方式，该技术利用聚焦超声以机械方式液化并破坏目标组织，降低与手术、放疗及其他常规疗法相关的多种并发症和副作用风险。 HistoSonics董事长兼首席执行官Mike Blue表示：“本次申请是组织摧毁术的适用范围从肝脏拓展至肾脏领域的重要里程碑，肾脏领域的患者和临床医生均在寻求可保留器官、保护肾单位的替代治疗方案。我们认为，组织摧毁术有潜力从根本上改变实体肿瘤的治疗方式，提供精准、无创的疗法，守护好最重要的方面——包括患者生活质量。” 本次申请由正在开展的#HOPE4KIDNEY临床试验(NCT05820087)的临床证据作为支撑。该试验为前瞻性、多中心、单臂关键性临床试验，旨在评估Edison®系统用于破坏目标肾脏肿瘤的安全...

MINNEAPOLIS--(BUSINESS WIRE)--HistoSonics, développeur de l’Edison® Histotripsy System et d’une nouvelle plateforme thérapeutique d’histotripsie, a annoncé aujourd’hui avoir déposé une demande De Novo auprès de la Food and Drug Administration (FDA) américaine afin d’obtenir l’autorisation d’étendre l’utilisation de son Edison® Histotripsy System à la destruction des tumeurs rénales. Cette étape marque une avancée significative dans la mission de l’entreprise visant à transformer le traitement d...